HTA202 Health Technology Assessment (HTA) and Reimbursement Decisions for the New Anti-IL-13 Monoclonal Antibody Lebrikizumab for Patients With Moderate to Severe Atopic Dermatitis (AD) in Europe
Abstract
Authors
L. Solé-Feu B Akmaz JM Joubert M Cressey M del Barrio